Last reviewed · How we verify

Actomol — Competitive Intelligence Brief

Actomol (MEBANAZINE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoamine Oxidase Inhibitors. Area: Neuroscience.

marketed Monoamine Oxidase Inhibitors Amine oxidase [flavin-containing] A Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Actomol (MEBANAZINE).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Actomol TARGET MEBANAZINE marketed Monoamine Oxidase Inhibitors Amine oxidase [flavin-containing] A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoamine Oxidase Inhibitors class)

  1. · 7 drugs in this class
  2. Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Actomol — Competitive Intelligence Brief. https://druglandscape.com/ci/mebanazine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: